Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The present study was conducted to determine and compare the target attainment rate (TAR) between microorganism-nonspecific (C_trough) and microorganism-specific (AUC_24/MIC) targets over two weeks of teicoplanin administration according to several dose regimens for the treatment of Staphylococcus aureus in Korean patients with neutropenic fever. Materials and Methods: One thousand virtual concentrations were obtained for each dose using the population pharmacokinetic parameters of teicoplanin adopted from a published study. Simulation of 1,000 virtual MICs was performed using the MICs of 78 clinical isolates of S. aureus collected from a hospital in Korea. Thereafter, these simulated MICs were randomly allocated to 1,000 virtual patients in whom the TARs for AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L were determined. The relationship of the maintenance dose with the steady-state TAR was predicted with respect to the AUC_24/MIC >125 [or 345] using logistic analysis. Results: The standard dose regimen of teicoplanin showed TARs of about 70% [or 33%] and 70% [or 20%] at steady-state in cases with AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L, respectively. Conclusion: The current standard dose regimen was predicted to be insufficient to adequately treat S. aureus in Korean patients with neutropenic fever. To assure at least an 80% TAR in this population, dose adjustment of teicoplanin should be considered.
Abstract
Purpose: The present study was conducted to determine and compare the target attainment rate (TAR) between microorganism-nonspecific (C_trough) and microorganism-specific (AUC_24/MIC) targets over two weeks of teicoplanin administration according to several dose regimens for the treatment of Staphylococcus aureus in Korean patients with neutropenic fever. Materials and Methods: One thousand virtual concentrations were obtained for each dose using the population pharmacokinetic parameters of teicoplanin adopted from a published study. Simulation of 1,000 virtual MICs was performed using the MICs of 78 clinical isolates of S. aureus collected from a hospital in Korea. Thereafter, these simulated MICs were randomly allocated to 1,000 virtual patients in whom the TARs for AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L were determined. The relationship of the maintenance dose with the steady-state TAR was predicted with respect to the AUC_24/MIC >125 [or 345] using logistic analysis. Results: The standard dose regimen of teicoplanin showed TARs of about 70% [or 33%] and 70% [or 20%] at steady-state in cases with AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L, respectively. Conclusion: The current standard dose regimen was predicted to be insufficient to adequately treat S. aureus in Korean patients with neutropenic fever. To assure at least an 80% TAR in this population, dose adjustment of teicoplanin should be considered.
참고문헌 (26)
- Sun Hee Park, "Current Trends of Infectious Complications following Hematopoietic Stem Cell Transplantation in a Single Center", Journal of Korean Medical Science, 21(2), pp.199~207 (2006), 대한의학회
- 이동건, "호중구 감소성 발열환자에게 경험적으로 투여한 Teicoplanin의 효과", Infection and Chemotherapy, 36(2), pp.83~91 (2004), 대한감염학회
- Wilson AP, "Clinical pharmacokinetics of teicoplanin", Clin Pharmacokinet, 39, pp.167~183 (2000)
- MacGowan AP, "Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides", Ther Drug Monit, 20, pp.473~477 (1998)
- Harding I, "Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome", J Antimicrob Chemother, 45, pp.835~841 (2000)
- MacGowan AP, "Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome", J Infect Chemother, 2, pp.197~208 (1996)
- Hyatt JM, "The importance of pharmacokinetic", pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents, 1995, pp.28, 143~160
- risk ratio: a handbook for the rational use of potentially hazardous drugs, "The benefit", pp.1999, Korting HC
- Moise PA, "Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus", Am J Health Syst Pharm, 57(Suppl 2), pp.S4~S9 (2000)
- Craig WA, "Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid", Infect Dis Clin North Am, 17, pp.479~501 (2003)
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing. Sixteenth inforclinical mational supplement. Approved standard M100-S16", ~ (2006)
- Lortholary O, "Population pharmacokinetic study of teicoplanin in severely neutropenic patients", Antimicrob Agents Chemother, 40, pp.1242~1247 (1996)
- Svetitsky S, "Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis", Antimicrob Agents Chemother, 53, pp.4069~4079 (2009)
- Whitehouse T, "Pharmacokinetic studies of linezolid and teicoplanin in the critically ill", J Antimicrob Chemother, 55, pp.333~340 (2005)
- Gimenez F, "Variations of teicoplanin concentrations in neutropenic patients", J Clin Pharm Ther, 22, pp.187~190 (1997)
- Schentag JJ, "Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit", Crit Care Med, 29, pp.N100~N107 (2001)
- Pea F, "Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose", J Antimicrob Chemother, 51, pp.971~975 (2003)
- Lortholary O, "Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia", Lancet Infect Dis, 8, pp.612~620 (2008)
- Pea F, "Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages", Clin Pharmacokinet, 43, pp.405~415 (2004)
- Van Bambeke F, "Glycopeptides in clinical development: pharmacological profile and clinical perspectives", Curr Opin Pharmacol, 4, pp.471~478 (2004)
- McKinnon PS, "Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases", Eur J Clin Microbiol Infect Dis, 23, pp.271~288 (2004)
- Moise-Broder PA, "Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections", Clin Pharmacokinet, 43, pp.925~942 (2004)
- Stass H, "The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints", Infection, 33(Suppl 2), pp.29~35 (2005)
- Rybak MJ, "Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists", Clin Infect Dis, 49, pp.325~327 (2009)
- Kuti JL, "Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil", Clin Microbiol Infect, 14, pp.116~123 (2008)
- Weinbren M, "Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy", J Antimicrob Chemother, 50, pp.306~307 (2002)